We are currently investigating intermittent issues affecting access to some articles and pages on our site. We apologize for any inconvenience and are working to resolve this as quickly as possible.

IN BRIEF: Poolbeg Pharma notes Gilead interest in Hookipa fundraise

Poolbeg Pharma PLC - London-based clinical stage biopharmaceutical firm - Updates on Gilead ...

Alliance News 10 January, 2025 | 4:07PM
Email Form Facebook Twitter LinkedIn RSS

Poolbeg Pharma PLC - London-based clinical stage biopharmaceutical firm - Updates on Gilead Sciences Inc's intentions regarding potential Hookipa Pharma Inc combination. Notes its intention to vote in line with the board of Hookipa in the instance of a formal offer and that it will participate in the proposed concurrent fundraise in an amount up to USD8.7 million. Says this is consistent with its existing contractual obligations. Hookipa intends to fundraise up to approximately USD30 million. Gilead currently owns a 19% stake in Hookipa. Poolbeg notes that all combination discussions have been non-binding in nature with no certainty present that a formal offer will be made.

Current stock price: 5.40 pence, down 3.6% on Friday afternoon in London

12-month change: down 45%

By Christopher Ward, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2025 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Poolbeg Pharma PLC Ordinary Shares 5.45 GBX -2.68 -
Gilead Sciences Inc 89.14 USD -1.64

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2025 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures